![5-(3,3-二甲基-1-丁炔-1-基)-3-[(顺式-4-羟基环己基)[(反式-4-甲基环己基)羰基]氨基]-2-噻吩甲酸](https://stcdn.activebiopharma.com/active/ABP000275.png)
化学名称 : 5-(3,3-二甲基-1-丁炔-1-基)-3-[(顺式-4-羟基环己基)[(反式-4-甲基环己基)羰基]氨基]-2-噻吩甲酸
CAS : 1026785-59-0
英文名称: VX-222/VX222
英文同义词: VX-222
溶解度:Unknown
储存条件:at -20
生物活性
VX-222 (HCV Infection) is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection. While the protease inhibitors (telaprevir and boceprevir) are the directly-targeted anti-HCV agents furthest along in the development pipeline, HCV polymerase - an enzyme responsible for copying viral genetic material-is also a promising target. VX-222 is a novel non-nucleoside HCV NS5B polymerase inhibitor with potent in vitro activity. [1]
参考文献
[1] 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010).2010 April 14-18; Vienna, Austria
Bortezomib/Velcade, MG-341, PS-341
179324-69-7
Ehp-inhibitor-1
861249-59-4
Celecoxib/Celebrex, Celebra
169590-42-5
(2S)-1-[3-乙基-7-[[(1-氧代-3-吡啶基)甲基]氨基]吡唑并[1,5-A]嘧啶-5-基]-2-哌啶乙醇
779353-01-4